National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing 400038, PR China.
Department of Biological and Chemical Engineering, Chongqing University of Education, Chongqing 400067, PR China.
Clin Immunol. 2018 Mar;188:85-93. doi: 10.1016/j.clim.2017.12.012. Epub 2017 Dec 28.
With more and more drug-resistant Staphylococcus aureus strains emerging in hospitals, there is an urgent need to develop an effective vaccine to combat S. aureus infection. In this study, we constructed a novel bivalent fusion vaccine, SpA-D-FnBPA (SF), based on the D domain of staphylococcal protein A (SpA) and the A domain of fibronectin-binding protein A (FnBPA). Immunisation with SF induced a more ideal protective effect compared with the single components alone in a sepsis model. It also showed broad immunoprotection against seven FnBPA isotypes. Vaccination with SF induced strong antibodies responses and Th1/Th17 polarized cellular responses. Further we demonstrated the protective effect of antibodies by the opsonophagocytic assay (OPA) and passive immunisation. Moreover, vaccination with SF showed protective efficacy in a murine pneumonia model and skin abscess model. These results suggest that SF can be regarded as a promising vaccine candidate for the prevention of S. aureus infections.
随着越来越多的耐甲氧西林金黄色葡萄球菌（MRSA）菌株在医院中出现，迫切需要开发一种有效的疫苗来对抗金黄色葡萄球菌感染。在本研究中，我们构建了一种新型双价融合疫苗 SpA-D-FnBPA（SF），该疫苗基于金黄色葡萄球菌蛋白 A（SpA）的 D 结构域和纤连蛋白结合蛋白 A（FnBPA）的 A 结构域。在败血症模型中，SF 免疫诱导的保护效果优于单一成分。它还显示出针对七种 FnBPA 同种型的广泛免疫保护。SF 疫苗接种可诱导强烈的抗体反应和 Th1/Th17 极化的细胞反应。我们进一步通过调理吞噬测定（OPA）和被动免疫证明了抗体的保护作用。此外，SF 疫苗接种在小鼠肺炎模型和皮肤脓肿模型中显示出保护效力。这些结果表明，SF 可作为预防金黄色葡萄球菌感染的有前途的疫苗候选物。
